- Home
- SXTP vs BJDX Comparison
SXTP vs BJDX Comparison
Compare SXTP & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- BJDX
- Stock Information
- Founded
- SXTP 2010
- BJDX 2015
- Country
- SXTP United States
- BJDX United States
- Employees
- SXTP N/A
- BJDX N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- BJDX Medical Specialities
- Sector
- SXTP Health Care
- BJDX Health Care
- Exchange
- SXTP Nasdaq
- BJDX Nasdaq
- Market Cap
- SXTP 3.0M
- BJDX 3.3M
- IPO Year
- SXTP 2023
- BJDX 2021
- Fundamental
- Price
- SXTP $1.04
- BJDX $0.10
- Analyst Decision
- SXTP Buy
- BJDX
- Analyst Count
- SXTP 2
- BJDX 0
- Target Price
- SXTP $28.80
- BJDX N/A
- AVG Volume (30 Days)
- SXTP 87.5K
- BJDX 2.7M
- Earning Date
- SXTP 11-18-2024
- BJDX 11-07-2024
- Dividend Yield
- SXTP N/A
- BJDX N/A
- EPS Growth
- SXTP N/A
- BJDX N/A
- EPS
- SXTP N/A
- BJDX N/A
- Revenue
- SXTP $441,255.00
- BJDX N/A
- Revenue This Year
- SXTP $267.05
- BJDX N/A
- Revenue Next Year
- SXTP $181.82
- BJDX N/A
- P/E Ratio
- SXTP N/A
- BJDX N/A
- Revenue Growth
- SXTP 12.07
- BJDX N/A
- 52 Week Low
- SXTP $0.92
- BJDX $0.10
- 52 Week High
- SXTP $18.36
- BJDX $38.96
- Technical
- Relative Strength Index (RSI)
- SXTP 39.03
- BJDX 22.67
- Support Level
- SXTP $0.92
- BJDX $0.10
- Resistance Level
- SXTP $1.38
- BJDX $0.14
- Average True Range (ATR)
- SXTP 0.11
- BJDX 0.01
- MACD
- SXTP 0.01
- BJDX 0.01
- Stochastic Oscillator
- SXTP 26.72
- BJDX 7.45
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.